



TARIFF APPENDIX

Disease-specific reimbursement schedules and tariffs for covered conditions. To be used together with the Tariff Operational Manual.



GHANA MEDICAL TRUST FUND

Established under Act 1144, 2025

TARIFF APPENDIX

Disease-specific reimbursement schedules and tariffs for conditions covered by the Ghana Medical Trust Fund. To be used together with the Tariff Operational Manual.

Version 1.0 | 2026

Issued by:
Ghana Medical Trust Fund

HOW TO USE THIS TARIFF APPENDIX

This Tariff Appendix accompanies the GMTF Tariffs Operational Manual and sets out the disease-specific reimbursement schedules for all eight cancers currently covered by the Ghana Medical Trust Fund. It should be read and used together with the Operational Manual.

Each section of this Appendix covers one cancer and is divided into three parts:

- A narrative explaining the clinical management pathway, the treatment options available, and the key cost drivers for that cancer.
- A tariff schedule table showing, for each treatment phase and each line item, the frequency, unit cost, per treatment option.
- Investigations grouping breakdowns showing the individual components of investigations that make up each grouped investigation line item in the tariff table. These groupings represent a standard package of tests required to achieve a single clinical objective (for example, diagnosis, staging or monitoring) and are priced as a single unit. The grouping breakdown is provided to enable service providers understand exactly which tests are included. Providers must submit claims for only investigations actually conducted.

IMPORTANT: A patient must never be charged separately for individual tests that are listed as components of a named grouping.

NOTE:

- All costs are in Ghana Cedis (GHS) and represent the rates applicable for reimbursement by the GMTF to Certified Health Care Providers (CHCPs).
- Items marked with an asterisk (*) require pre-authorisation from the GMTF before the service is provided. Claims for asterisked items submitted without documented prior authorisation will not be reimbursed.



TABLE OF CONTENTS

APPENDIX 1: TARIFFS BY CONDITION	5
1. Burkitt Lymphoma [BL]	5
1.1 Tariff Narrative	5
1.2 Tariff Schedule	5
1.3 Investigation Grouping Breakdown	6
2. Soft Tissue Sarcoma	7
2.1 Tariff Narrative	7
2.2 Tariff Schedule	7
2.3 Investigation Grouping Breakdowns	8
3. Wilms Tumour (Nephroblastoma)	10
3.1 Tariff Narrative	10
3.2 Tariff Schedule	10
3.3 Investigation Grouping Breakdowns	11
4. Retinoblastoma	13
4.1 Tariff Narrative	13
4.2 Tariff Schedule	13
4.3 Investigation Grouping Breakdown	14
5. Acute Lymphoblastic Leukaemia (ALL)	16
5.1 Tariff Narrative	16
5.2 Tariff Schedule	16
5.3 Investigation Grouping Breakdowns	17
6. Cervical Cancer	21
6.1 Tariff Narrative	21
6.2 Tariff Schedule	21
6.3 Investigation Grouping Breakdowns	22
7. Breast Cancer	24
7.1 Tariff Narrative	24
7.2 Tariff Schedule	24
7.3 Investigation Grouping Breakdowns	26
8. Prostate Cancer	29
8.1 Clinical Overview and Tariff Narrative	29
8.2 Tariff Schedule	29
8.3 Investigation Grouping Breakdowns	30
APPENDIX 2: LIST OF INVESTIGATIONS AND TARIFFS	32

APPENDIX 1: TARIFFS BY CONDITION

1. Burkitt Lymphoma [BL]

1.1 Tariff Narrative

The GMTF covers BL for patients aged under 18 years. Two treatment options are covered, corresponding to disease localisation at presentation with or without inpatient admission. Both options include two treatment response assessments, each comprising an outpatient consultation and a CT scan. All consultations are covered as outpatient visits. Chemotherapy is administered on an inpatient basis for cycles requiring hospitalisation; the relevant admission costs are included in the tariff. Drug costs are not included in the tariff; these are claimed separately under the GMTF Medicines List.

The Burkitt Lymphoma Investigations grouping covers the complete diagnostic and staging workup at the time of first presentation. This is a single grouped cost representing investigations required to confirm the diagnosis, determine disease stage, assess organ function, and screen for infections that affect treatment safety. Providers shall only claim for specific investigations conducted.

1.2 Tariff Schedule

Phase	Item / Service	Frequency	Cost (GHS)
DIAGNOSIS & STAGING			
	Outpatient consultation	2	349.06
	Burkitt Lymphoma Investigations (Grouping) - See breakdown below	1	15,141.10
TREATMENT			
1. COP (1 cycle)	Inpatient admission — 3 days	3	289.78
	Chemotherapy consumables	2	339.30
2. R-COPADM (3 cycles)	Inpatient admission — 5 days	5	289.78
	Chemotherapy consumables	3	339.30
Treatment Response Assessment 1	Outpatient consultation	1	349.06
3. R-CYM (3 cycles)	Outpatient consultation	3	349.06
	Chemotherapy consumables	3	339.30
Treatment Response Assessment 2	Outpatient consultation	1	349.06
	CT scan (1 region + contrast)*	1	2,560.00

**Pre-authorisation required*

1.3 Investigation Grouping Breakdown

The following breakdown shows all investigations included in the Burkitt Lymphoma Investigations grouping. This grouping covers the complete diagnostic and staging workup at the time of presentation.

Grouping: Burkitt Lymphoma Investigations

Component Investigation	Frequency in Grouping	Unit Cost (GHS)
Histopathology (medium sample)	1	400.00
Immunostaining*	1	1,795.54
Cytology — Cerebrospinal Fluid (CSF)	8	100.00
Echocardiogram	3	400.00
Bone Marrow Aspirate	1	318.70
CT Scan — 1 Region + IV Contrast*	3	1,600.00
Plain X-ray (musculoskeletal, 1 region)	1	110.00
Ultrasound — 1 region	1	250.00
Prothrombin Time / INR	1	65.44
Blood Grouping & Antibody Screen	1	110.00
Ultrasound-Guided Biopsy	1	648.50
Serum Lactate Dehydrogenase (LDH)	1	72.00
Serum Inorganic Phosphate	2	69.50
HIV Screening	2	46.30
Paediatric Tests (standard panel)	8	461.16
Routine Stool Examination	1	15.00
Serum Uric Acid	2	114.80
Ionised Calcium	2	79.90

****Pre-authorisation required***

2. Soft Tissue Sarcoma

2.1 Tariff Narrative

The GMTF covers Soft Tissue Sarcoma (STS) for children under 18 years. Two treatment options are covered, based on the anatomical location and depth of the primary tumour. Both options include 4 cycles of pre-operative CVADo chemotherapy, a treatment response MRI assessment, surgery with anaesthesia, and 5 cycles of post-operative CVA chemotherapy. Each chemotherapy cycle includes an outpatient consultation, consumables, and a follow-up investigation grouping. A short inpatient admission (1 day) is included for each pre-operative chemotherapy cycle.

The Regular Investigations grouping covers the full diagnostic and staging workup at first presentation. The Chemotherapy Treatment Investigations grouping covers the monitoring tests required during each chemotherapy cycle (FBC, BUE&Cr, LFT, CSF cytology, and packed red cells). These monitoring tests ensure safe administration of chemotherapy and must not be billed separately from the grouping.

IMPORTANT: Adjunct radiotherapy for STS requires pre-authorisation from the GMTF before treatment commences.

2.2 Tariff Schedule

Phase	Item / Service	Frequency	Cost (GHS)
DIAGNOSIS & STAGING			
	Outpatient consultation	2	GHS 349.06
	STS Regular Investigations (Grouping) — See breakdown below	1	GHS 11,779.69
	STS Additional Investigations (Grouping)	1	GHS 1,500.00
PRE-OP CHEMOTHERAPY CVADo — 4 cycles			
	Outpatient consultation	3	GHS 349.06
	Chemotherapy consumables	4	GHS 339.30
	STS Chemo Treatment Investigations (Grouping) — See breakdown below	4	GHS 1,604.78
	Inpatient admission — 1 day	1	GHS 1,064.76
RESPONSE ASSESSMENT			
	Outpatient consultation	1	GHS 349.06
	MRI — 1 region + contrast*	1	GHS 2,250.00
SURGERY			
Excision biopsy	Excision biopsy — superficial mass	1	GHS 1,716.47



Phase	Item / Service	Frequency	Cost (GHS)
	Excision biopsy — deep mass	1	GHS 4,056.13
Anaesthesia	Anaesthesia — superficial excision	1	GHS 2,387.66
	Anaesthesia — deep excision	1	GHS 2,787.66
POST-OP CHEMOTHERAPY CVA — 5 cycles			
	Outpatient consultation	5	GHS 349.06
	Chemotherapy consumables	5	GHS 339.30
	STS Chemo Treatment Investigations (Grouping) — <i>See breakdown below</i>	5	GHS 1,604.78
POST-OP RESPONSE ASSESSMENT			
	MRI — 1 region + contrast*	1	GHS 2,250.00
ADJUNCT RADIOTHERAPY*			
	EBRT technique — per fraction	25	GHS 510.00
	Radiotherapy consumables — per fraction	25	GHS 112.50

**Pre-authorisation required*

2.3 Investigation Grouping Breakdowns

Grouping: STS Regular Investigations (Diagnostic & Staging Grouping)

Component Investigation	Frequency in Grouping	Unit Cost (GHS)
Paediatric Tests (standard panel)	1	GHS 461.16
Hepatitis B Surface Antigen (HBsAg)	1	GHS 41.86
Hepatitis C Screening	1	GHS 41.86
HIV Screening	1	GHS 46.30
Routine Stool Examination	1	15.00
MRI — 1 region + contrast*	1	GHS 2,250.00
CT Scan — 2 regions + contrast*	1	GHS 1,851.88
Ultrasound-Guided Biopsy	1	GHS 648.50
Immunostaining*	1	GHS 1,795.54
Bone Marrow Aspirate	1	GHS 318.70
Flow Cytometry for Immunophenotyping	1	GHS 2,600.00
Serum Uric Acid	1	GHS 114.80
Ionised Calcium	1	GHS 79.90
Plain X-ray (musculoskeletal, 1 region)	1	GHS 110.00
Blood Grouping & Antibody Screen	1	GHS 110.00
Bleeding and Clotting Time	1	GHS 259.50



Component Investigation	Frequency in Grouping	Unit Cost (GHS)
Ultrasound — 1 region	1	GHS 250.00
Serum Lactate Dehydrogenase (LDH)	1	GHS 72.00
Serum Inorganic Phosphate	1	GHS 69.50
Histopathology (small sample)	1	GHS 336.60

****Pre-authorisation required***

Grouping: STS Additional Investigations Grouping

Component Investigation	Frequency in Grouping	Unit Cost (GHS)
Basic Cytogenetic Panel (PCR / FISH / NGS)	1	—
Cytology — Cerebrospinal Fluid (CSF)	1	100.00
Bone Scan*	1	1400.00

****Pre-authorisation required***

Grouping: STS Chemotherapy Treatment Investigations Grouping (per chemotherapy cycle)

Component Investigation	Frequency in Grouping	Unit Cost (GHS)
Full Blood Count (FBC — automation)	1	95.33
BUE & Creatinine	1	114.80
Liver Function Tests (LFT)	1	155.33
Cytology — Cerebrospinal Fluid (CSF)	1	100.00
Concentrated Red Blood Cells	1	235.00

3. Wilms Tumour (Nephroblastoma)

3.1 Tariff Narrative

The GMTF covers Wilms Tumour for patients aged under 18 years. Three treatment options are covered, corresponding to disease extent at presentation. All options include a response assessment CT scan after pre-operative chemotherapy (before surgery) and a second CT scan after completion of all treatment. A single inpatient admission (1 day) is included for each chemotherapy cycle. The surgical procedure (Wilms Tumour nephrectomy) and anaesthesia are included as separate line items.

The Wilms Tumour Diagnostic & Staging Investigations grouping covers a comprehensive panel of investigations required at first presentation. The Wilms Tumour Chemotherapy Follow-up Investigation grouping covers the monitoring tests (FBC, LFT, BUE&Cr) required at each chemotherapy visit.

3.2 Tariff Schedule

Phase	Item / Service	Frequency	Cost (GHS)
DIAGNOSIS & STAGING			
	Outpatient consultation	2	GHS 349.06
	WT Diagnostic & Staging Investigations (Grouping) — See breakdown below	1	GHS 9,488.36
PRE-OP CHEMOTHERAPY			
Localised — 4 cycles	Outpatient consultation	3	GHS 349.06
	Chemotherapy consumables	4	GHS 339.30
	WT Chemo Follow-up Investigations (Grouping, per cycle)	2	GHS 365.46
Advanced — 5 cycles	Outpatient consultation	5	GHS 349.06
	Chemotherapy consumables	5	GHS 339.30
	WT Chemo Follow-up Investigations (Grouping, per cycle)	6	GHS 365.46
Inpatient	Admission — 1 day	1	GHS 289.78
RESPONSE ASSESSMENT 1 (Pre-surgery)			
	Outpatient consultation	1	GHS 349.06
	CT scan — 2 regions + 2 contrast*	1	GHS 3,079.56
SURGERY			
	Wilms Tumour surgery (nephrectomy)	1	GHS 4,056.13
	Anaesthesia — Wilms Tumour surgery	1	GHS 2,787.66



Phase	Item / Service	Frequency	Cost (GHS)
RADIOTHERAPY			
Stage III — 20 fractions	EBRT technique — per fraction	20	GHS 510.00
	Radiotherapy consumables — per fraction	20	GHS 112.50
POST-OP CHEMOTHERAPY			
Localised — 9 cycles	Outpatient consultation	9	GHS 349.06
	Chemotherapy consumables	9	GHS 339.30
	WT Chemo Follow-up Investigations (Grouping, per cycle)	9	GHS 365.46
Advanced — 12 cycles	Outpatient consultation	12	GHS 349.06
	Chemotherapy consumables	12	GHS 339.30
	WT Chemo Follow-up Investigations (Grouping, per cycle)	12	GHS 365.46
RESPONSE ASSESSMENT 2 (Post-treatment)			
	CT scan — 2 regions + 1 contrast*	1	GHS 2,247.41
ADJUNCT RADIOTHERAPY FOR LOCAL RECURRENCE*			
14 fractions	EBRT technique — per fraction	14	GHS 510.00
	Radiotherapy consumables — per fraction	14	GHS 112.50

**Pre-authorisation required*

3.3 Investigation Grouping Breakdowns

Grouping: Wilms Tumour Diagnostic & Staging Investigations Grouping

Component Investigation	Frequency in Grouping	Unit Cost (GHS)
Histopathology (extra-large sample)	1	965.00
Immunostaining*	1	1,795.54
CT Scan — 2 regions + contrast*	1	2,247.41
Paediatric Tests (standard panel) — <i>See breakdown below</i>	1	461.16
CT Scan — 1 region + IV contrast*	1	1,600.00
Ionised Calcium	1	79.90
Serum Uric Acid	1	114.80
2-hour Post-prandial Blood Glucose	1	59.40

Component Investigation	Frequency in Grouping	Unit Cost (GHS)
BUE & Creatinine	1	114.80
Liver Function Tests (LFT)	1	155.33
Concentrated Red Blood Cells	1	235.00
Ultrasound-Guided Biopsy	1	648.50
Hepatitis B Surface Antigen (HBsAg)	1	41.86
Hepatitis C Screening	1	41.86
HIV Screening	1	46.30
Routine Stool Examination	1	15.00
Serum Lactate Dehydrogenase (LDH)	1	72.00
Ultrasound — 1 region	1	250.00
Plain X-ray (musculoskeletal, 1 region)	1	110.00
Blood Grouping & Crossmatching	1	110.00
Bleeding and Clotting Time	1	259.50
Routine Urine Examination	1	16.50

Grouping: Paediatric Tests (Standard Panel)

Test/Investigation	Frequency in Grouping	Unit Costs (GHS)
BUE & Creatinine	1	114.80
Full Blood Count (Automation)	1	95.33
Routine Urine Examination	1	16.50
Haemoglobin Electrophoresis	1	13.80
LFT	1	155.33
Malaria RDT	1	6.00
Fasting Plasma Glucose / Random Plasma Glucose	1	59.40

Grouping: Wilms Tumour Chemotherapy Follow-up Investigations Grouping (per cycle)

Component Investigation	Frequency in Grouping	Unit Cost (GHS)
Full Blood Count (FBC — automation)	1	95.33
Liver Function Tests (LFT)	1	155.33
BUE & Creatinine	1	114.80

4. Retinoblastoma

4.1 Tariff Narrative

The GMTF covers Retinoblastoma for patients aged under 18 years. The diagnosis and staging process includes examination of the eye under general anaesthesia, the cost of which (procedure fee plus anaesthesia) is included as a separate line item. The Retinoblastoma Investigations grouping covers separate investigations required to stage the disease, assess organ function, and screen for infections. Enucleation surgery includes the cost of the orbital implant, which is integral to the procedure.

IMPORTANT: Adjunct radiotherapy for Retinoblastoma requires pre-authorisation from the GMTF. Claims for radiotherapy submitted without documented pre-authorisation will not be reimbursed.

4.2 Tariff Schedule

Phase	Item / Service	Frequency	Cost (GHS)
DIAGNOSIS & STAGING			
	Outpatient consultation	2	GHS 349.06
	Retinoblastoma Investigations (Grouping) — See grouping breakdown below	1	GHS 11,085.73
	Examination of eye under anaesthesia (procedure)	1	GHS 390.67
	Anaesthesia — examination under anaesthesia	1	GHS 1,664.54
PRE-OPERATIVE CHEMOTHERAPY (2 cycles)			
	Outpatient consultation	2	GHS 349.06
	Chemotherapy consumables	2	GHS 339.30
	Inpatient admission — 3 days	3	GHS 396.49
TREATMENT RESPONSE ASSESSMENT (Pre-surgery)			
	Outpatient consultation	1	GHS 349.06
	Examination of eye under anaesthesia (procedure)	1	GHS 390.67
	Anaesthesia — examination under anaesthesia	1	GHS 1,664.54
SURGERY			
	Enucleation (removal of eyeball)	1	GHS 1,357.07
	Anaesthesia — enucleation	1	GHS 2,178.92
	Orbital implant (integral to surgery)	1	GHS 3,300.00



Phase	Item / Service	Frequency	Cost (GHS)
POST- OPERATIVE CHEMOTHERAPY (4 cycles)			
	Outpatient consultation	4	GHS 349.06
	Chemotherapy consumables	4	GHS 339.30
POST- OPERATIVE TREATMENT RESPONSE ASSESSMENT			
	Outpatient consultation	4	GHS 349.06
ADJUNCT RADIOTHERAPY*			
25 fractions	Radiotherapy EBRT technique — per fraction	25	GHS 510.00
	Radiotherapy consumables — per fraction	25	GHS 112.50
POST- RADIOTHERAPY TREATMENT RESPONSE ASSESSMENT			
Post-RT follow-up	Outpatient consultation	4	GHS 349.06

****Pre-authorisation required***

4.3 Investigation Grouping Breakdown

Grouping: Retinoblastoma Investigations Grouping (Diagnostic & Staging)

Component Investigation	Frequency in Grouping	Unit Cost (GHS)
Histopathology (medium sample)	1	400.00
Immunostaining*	1	1,795.54
Cytology — Cerebrospinal Fluid (CSF)	3	100.00
MRI — 2 regions + contrast*	2	2,650.00
Bone Marrow Aspirate	1	318.70
Full Blood Count (FBC — automation)	6	95.33
Liver Function Tests (LFT)	2	155.33
Ionised Calcium	2	79.90
Serum Uric Acid	2	114.80
Paediatric Tests (standard panel) - See breakdown below	2	461.16
Routine Urine Examination	1	16.50
BUE & Creatinine	6	114.80
Serum Inorganic Phosphate	2	69.50
HIV Screening	2	46.30

****Pre-authorisation required***

**Grouping: Paediatric Tests (Standard Panel)**

Test/Investigation	Frequency in Grouping	Unit Costs (GHS)
BUE & Creatinine	1	114.80
Full Blood Count (Automation)	1	95.33
Routine Urine Examination	1	16.50
Haemoglobin Electrophoresis	1	13.80
LFT	1	155.33
Malaria RDT	1	6.00
Fasting Plasma Glucose / Random Plasma Glucose	1	59.40

5. Acute Lymphoblastic Leukaemia (ALL)

5.1 Tariff Narrative

The GMTF covers Acute Lymphoblastic Leukaemia for patients aged under 18 years. At several points in the treatment protocol, specialised investigations marked with an asterisk (*) may be required. These include a basic cytogenetic panel (PCR/FISH/NGS), and Minimal Residual Disease (MRD) testing (B-Cell and T-Cell). These investigations are included in the tariff schedule but require prior authorisation from the GMTF before they are performed.

IMPORTANT: Claims submitted without documented prior authorisation for these tests will not be reimbursed.

Each investigation grouping covers the specific blood and laboratory tests required during that treatment phase. These groupings are designed to monitor for bone marrow response, haematological toxicity, organ function, and central nervous system involvement. All items within a grouping are priced as a single unit. Providers must only submit claims for investigations actually conducted.

5.2 Tariff Schedule

Treatment Phase	Item / Service	Frequency	Cost (GHS)
DIAGNOSIS & STAGING			
	Outpatient consultation	2	GHS 349.06
	ALL Diagnosis Investigations (Grouping) — See grouping breakdown below	1	GHS 1,885.68
	Flow cytometry for immunophenotyping	1	GHS 2,600.00
	Basic cytogenetic panel (PCR/FISH/NGS)*	1	GHS 1,650.00
INDUCTION — 41 days			
	Inpatient admission — 14 days	1	GHS 2,646.43
	Outpatient consultation	4	GHS 349.06
	ALL Induction Investigations (Grouping) — See grouping breakdown below	1	GHS 11,763.12
	Flow Cytometry for Minimal Residual Disease (MRD) – T-cell	1	GHS 6,230.00
	Chemotherapy consumables	4	GHS 339.30
CONSOLIDATION — 56 days			
	Outpatient consultation	7	GHS 349.06
	ALL Consolidation Investigations (Grouping) — See grouping breakdown below	1	GHS 5,836.56



Treatment Phase	Item / Service	Frequency	Cost (GHS)
	Chemotherapy consumables	7	GHS 339.30
INTERIM MAINTENANCE I — 63 days			
	Inpatient admission — 5 days	1	GHS 1,005.84
	Outpatient consultation	3	GHS 349.06
	ALL Interim Maintenance I Investigations (Grouping) — <i>See grouping breakdown below</i>	1	GHS 5,402.14
	Chemotherapy consumables	9	GHS 339.30
DELAYED INTENSIFICATION I 56 days x2 cycles			
	Outpatient consultation	12	GHS 349.06
	Chemotherapy consumables	12	GHS 339.30
	ALL Delayed Intensification I Investigations (Grouping) — <i>See grouping breakdown below</i>	1	GHS 7,254.73
INTERIM MAINTENANCE II — 56 days			
	Outpatient consultation	6	GHS 349.06
	ALL Interim Maintenance II Investigations (Grouping) — <i>See grouping breakdown below</i>	1	GHS 1,763.83
	Chemotherapy consumables	6	GHS 339.30
DELAYED INTENSIFICATION II 56 days x2 cycles			
	Outpatient consultation	12	GHS 349.06
	Chemotherapy consumables	12	GHS 339.30
	ALL Delayed Intensification II Investigations (Grouping) — <i>See grouping breakdown below</i>	1	GHS 5,992.80
MAINTENANCE — 30 months 9 cycles of 84 days			
	Outpatient consultation	33	GHS 349.06
	Chemotherapy consumables	33	GHS 339.30
	ALL Maintenance Investigations (Grouping) — <i>See grouping breakdown below</i>	1	GHS 6,847.30
	MRD — T-Cell (end of maintenance)*	1	GHS 6,230.00

**Pre-authorisation required*

5.3 Investigation Grouping Breakdowns

Grouping: ALL Diagnosis Investigations Grouping

Component Investigation	Frequency in Grouping	Unit Cost (GHS)
Paediatric Tests (standard panel) — See grouping breakdown below	1	461.16
Full Blood Count with film comment	1	145.33
Bone Marrow Aspirate	1	318.70
Cytology — Cerebrospinal Fluid (CSF)	1	100.00
HIV Screening	1	46.30
Hepatitis C Screening	1	41.86
Ultrasound — 1 region	1	250.00
Plain X-ray (musculoskeletal, 1 region)	1	110.00
Serum Inorganic Phosphate	1	69.50
Bleeding and Clotting Time	1	259.50
Serum Lactate Dehydrogenase (LDH)	1	72.00
Glucose-6-Phosphate Dehydrogenase (G6PD)	1	165.30
Blood Grouping	1	88.00
Serum Uric Acid	1	114.80
Ionised Calcium	1	79.90
Hepatitis B Surface Antigen (HBsAg)	1	41.86

Grouping: Paediatric Tests (Standard Panel)

Test/Investigation	Frequency in Grouping	Unit Costs (GHS)
BUE & Creatinine	1	114.80
Full Blood Count (Automation)	1	95.33
Routine Urine Examination	1	16.50
Haemoglobin Electrophoresis	1	13.80
LFT	1	155.33
Malaria RDT	1	6.00
Fasting Plasma Glucose / Random Plasma Glucose	1	59.40

Grouping: ALL Induction Investigations Grouping

Component Investigation	Frequency in Grouping	Unit Cost (GHS)
Bone Marrow Aspirate	1	318.70
Full Blood Count (FBC — automation)	6	95.33
Concentrated Red Blood Cells	5	235.00
Platelets	20	170.00
Cytology — Cerebrospinal Fluid (CSF)	3	100.00
Blood Crossmatching	5	110.00

Grouping: ALL Consolidation Investigations Grouping



Component Investigation	Frequency in Grouping	Unit Cost (GHS)
Full Blood Count (FBC — automation)	7	95.33
Cytology — CSF	4	100.00
BUE & Creatinine	2	114.80
Liver Function Tests (LFT)	2	155.33
Blood Crossmatching	2	110.00
Concentrated Red Blood Cells	2	235.00
Platelets	8	170.00

Grouping: ALL Interim Maintenance I Investigations Grouping

Component Investigation	Frequency in Grouping	Unit Cost (GHS)
Full Blood Count (FBC — automation)	4	95.33
Cytology — CSF	2	100.00
BUE & Creatinine	2	114.80
Liver Function Tests (LFT)	2	155.33
Platelets	8	170.00
Concentrated Red Blood Cells	2	235.00
Blood Grouping & Antibody Screen	2	110.00

Grouping: ALL Delayed Intensification I Investigations Grouping

Component Investigation	Frequency in Grouping	Unit Cost (GHS)
Full Blood Count (FBC — automation)	12	95.33
Cytology — CSF	4	100.00
BUE & Creatinine	4	114.80
Liver Function Tests (LFT)	4	155.33
Platelets	4	170.00
Concentrated Red Blood Cells	4	235.00
Echocardiogram	2	400.00
Blood Grouping & Antibody Screen	4	110.00

Grouping: ALL Delayed Intensification II Investigations Grouping

Component Investigation	Frequency in Grouping	Unit Cost (GHS)
Full Blood Count (FBC — automation)	6	95.33
Cytology — CSF	2	100.00
BUE & Creatinine	2	114.80
Liver Function Tests (LFT)	2	155.33
Platelets	8	170.00
Concentrated Red Blood Cells	2	235.00
Blood Grouping & Antibody Screen	2	110.00



Component Investigation	Frequency in Grouping	Unit Cost (GHS)
Echocardiogram	1	400.00

Grouping: ALL Interim Maintenance II Investigations Grouping

Component Investigation	Frequency in Grouping	Unit Cost (GHS)
Full Blood Count (FBC — automation)	6	95.33
Cytology — CSF	2	100.00
BUE & Creatinine	2	114.80
Liver Function Tests (LFT)	2	155.33
Platelets	8	170.00
Concentrated Red Blood Cells	2	235.00
Blood Grouping & Antibody Screen	2	110.00
Echocardiogram	1	400.00

Grouping: ALL Maintenance Therapy Investigations Grouping (full 30-month period)

Component Investigation	Frequency in Grouping	Unit Cost (GHS)
Full Blood Count (FBC — automation)	33	95.33
Cytology — CSF	10	100.00
BUE & Creatinine	10	114.80
Liver Function Tests (LFT)	10	155.33

6. Cervical Cancer

6.1 Tariff Narrative

The GMTF covers cervical cancer in adult patients. All treatment options include a diagnosis phase (2 consultations, basic investigations, and where clinically indicated a colposcopy and biopsy under anaesthesia) and a staging phase (1 consultation, staging investigations including CT scan and, where indicated, MRI). Follow-up includes 2 consultations and a follow-up investigation grouping.

The Cervical Cancer Basic Diagnosis Investigations grouping covers a biopsy under local anaesthesia, histopathology, and FBC. The Cervical Cancer Staging Investigations grouping covers X-ray, CT scan (2 regions + contrast), BUE&Cr, HIV, FBC, and LFT. The Additional Staging Investigation grouping (MRI) is included for selected stages that require soft tissue delineation for treatment planning.

6.2 Tariff Schedule

Phase	Item / Service	Frequency	Cost (GHS)
DIAGNOSIS			
	OPD consultation	2	GHS 349.06
	Basic diagnosis investigations (Grouping) — See breakdown below	1	GHS 431.93
	Colposcopy & biopsy (procedure)	1	GHS 229.08
	Anaesthesia — colposcopy & biopsy	1	GHS 1,864.54
STAGING			
	OPD consultation	1	GHS 349.06
	Staging investigations (Grouping) — See breakdown below	1	GHS 2,769.17
	Additional staging — MRI 1 region + contrast*	1	GHS 2,250.00
TREATMENT — SURGERY			
Hysterectomy	OPD consultation	1	GHS 349.06
	Abdominal hysterectomy	1	GHS 5,942.45
	Anaesthesia — hysterectomy	1	GHS 4,187.03
Wertheim's operation	OPD consultation	1	GHS 349.06
	Wertheim's operation	1	GHS 6,655.06
	Anaesthesia: Wertheim's	1	GHS 7,706.44
TREATMENT — External Beam Radiotherapy (EBRT)			



Phase	Item / Service	Frequency	Cost (GHS)
30 fractions	OPD consultation (RT weeks)	30	GHS 349.06
	EBRT IMRT technique — per fraction	30	GHS 510.00
	Radiotherapy consumables — per fraction	30	GHS 112.50
TREATMENT — BRACHYTHERAPY			
4 sessions	3D brachytherapy — per session	4	GHS 1,057.66
	Radiotherapy consumables — per session	4	GHS 112.50
CONCURRENT CHEMOTHERAPY (Stage IB3–IIA+ only)			
6 cycles	Chemotherapy consumables	6	GHS 664.52
MAINTENANCE & FOLLOW-UP			
	OPD consultation	2	GHS 349.06
	Follow-up investigations (Grouping) — See breakdown below	2	GHS 365.46

**Pre-authorisation required*

6.3 Investigation Grouping Breakdowns

Grouping: Cervical Cancer Basic Diagnosis Investigations Grouping

Component Investigation	Frequency in Grouping	Unit Cost (GHS)
Histopathology (small sample)	1	336.60
Full Blood Count (FBC) [automated]	1	95.33

Grouping: Cervical Cancer Staging Investigations Grouping

Component Investigation	Frequency in Grouping	Unit Cost (GHS)
Plain X-ray (musculoskeletal, 1 region)	1	110.00
CT Scan — 2 regions + contrast*	1	2,247.41
BUE & Creatinine	1	114.80
HIV Screening	1	46.30
Full Blood Count (FBC)	1	95.33
Liver Function Tests (LFT)	1	155.33

**Pre-authorisation required*

Grouping: Cervical Cancer Follow-up Investigations Grouping (per follow-up visit)



Component Investigation	Frequency in Grouping	Unit Cost (GHS)
Full Blood Count (FBC) [automated]	1	95.33
BUE & Creatinine	1	114.80
Liver Function Tests (LFT)	1	155.33

7. Breast Cancer

7.1 Tariff Narrative

The GMTF covers breast cancer in adult patients. Four treatment options are covered, corresponding to disease stage and the combination of treatment modalities required. All options include a diagnosis phase (2 consultations and the basic diagnosis investigations grouping), a staging phase (basic staging CT scan), two response assessment cycles (covering CT scan, ultrasound, X-ray, and MRI), and maintenance monitoring. Hormonal therapy, targeted therapy, and immunotherapy are listed in the tariff schedule at zero cost because the drug costs for these agents are not included; they are covered under the GMTF Medicines List.

The Breast Cancer Basic Diagnosis Investigations grouping covers the core diagnostic workup: BUE&Cr, investigations for major operations under general anaesthesia (GA test), ultrasound-guided biopsy, FBC, ultrasound, immunostaining, and histopathology. The Additional Diagnosis Investigations grouping (CA 15-3, blood grouping, fine needle aspiration, large histopathology sample, mammogram) is included for selected options where a more detailed diagnostic workup is required.

NOTE: The maintenance phase includes consultations and follow-up investigations specific to the treatment modality received (surgery only, chemotherapy, hormonal therapy, radiotherapy, or targeted therapy). These are shown as separate items in the schedule. Providers should submit claims only for the maintenance items and investigations actually administered.

7.2 Tariff Schedule

Phase	Item / Service	Frequency	Cost (GHS)
DIAGNOSIS			
	OPD consultation	2	GHS 349.06
	Basic diagnosis investigations (Grouping) — See breakdown below	1	GHS 3,769.50
	Additional diagnosis investigations (Grouping)* — See breakdown below	1	GHS 963.80
STAGING			
	Basic staging: CT scan 2 regions + contrast	1	GHS 2,247.41
	Additional staging: Bone scan + CT + MRI (Grouping)* — See breakdown below	1	GHS 5,250.00
TREATMENT — SURGERY			
	Unilateral mastectomy	1	GHS 5,417.81
	Anaesthesia — mastectomy	1	GHS 2,587.66



Phase	Item / Service	Frequency	Cost (GHS)
TREATMENT — CHEMOTHERAPY			
Regular (6 cycles)	Chemotherapy consumables	6	GHS 339.30
Extended (8 cycles)	Chemotherapy consumables	8	GHS 339.30
TREATMENT — EBRT (20 fractions)			
Hybrid technique	EBRT per fraction — hybrid technique	20	GHS 958.00
MAINTENANCE			
Post-surgery OPD	OPD consultation (4 visits)	4	GHS 349.06
Chemotherapy OPD	OPD consultation per cycle (Regular)	6	GHS 349.06
	OPD consultation per cycle (Extended)	8	GHS 349.06
Hormonal therapy (Regular)	—	—	—
Hormonal therapy (Extended)	OPD consultation (8 visits)	8	GHS 349.06
Radiotherapy OPD	Radiotherapy OPD	6	GHS 349.06
	Targeted therapy OPD (Regular)	18	GHS 349.06
	Targeted therapy OPD (Extended)	18	GHS 349.06
	Radiotherapy consumables	6	GHS 112.50
POST-SURGERY FOLLOW-UP INVESTIGATIONS			
Post-surgery maintenance investigations	Basic: FBC, LFT, BUE&Cr (Grouping, x4) — <i>See breakdown below</i>	4	GHS 365.46
Chemotherapy maintenance investigations (Regular)	Chemo basic investigation grouping (x6) — <i>See breakdown below</i>	6	GHS 365.46
Chemotherapy maintenance investigations (Extended)	Chemo additional investigation grouping (x8) — <i>See breakdown below</i>	8	GHS 1,205.46
Hormonal therapy investigations (Regular)	Hormonal therapy basic investigation grouping (x4) — <i>See breakdown below</i>	4	GHS 270.13
Hormonal therapy investigations (Extended)	Hormonal therapy additional investigation grouping (x12) — <i>See breakdown below</i>	12	GHS 763.05
Radiotherapy investigations grouping	Radiotherapy investigations grouping (x6) — <i>See breakdown below</i>	6	GHS 365.46
Targeted therapy investigations (Regular)	Targeted therapy basic investigation grouping (x18) — <i>See breakdown below</i>	18	GHS 365.46

Phase	Item / Service	Frequency	Cost (GHS)
Targeted therapy investigations (Extended)	Targeted therapy additional investigation grouping (x18) — See breakdown below	18	GHS 1,605.46
RESPONSE ASSESSMENT (2 assessments)			
	Response assessment investigations (Grouping, x2) — See breakdown below	2	GHS 4,210.00

***Pre-authorisation required**

7.3 Investigation Grouping Breakdowns

Grouping: Breast Cancer Basic Diagnosis Investigations Grouping

Component Investigation	Frequency in Grouping	Unit Cost (GHS)
BUE & Creatinine	1	114.80
GA Tests (pre-operative) — See breakdown below	1	528.73
Ultrasound-Guided Biopsy	1	648.50
Full Blood Count (FBC)	1	95.33
Ultrasound — 1 region	1	250.00
Immunostaining*	1	1,795.54
Histopathology (small sample)	1	336.60

***Pre-authorisation required**

Grouping: Investigations for major operations under general anaesthesia (GA test)

Test/Investigation	Frequency in Grouping	Unit Cost (GHS)
BUE & Creatinine (Blood Urea & Creatinine)	1	114.80
Full Blood Count (FBC) – Automation	1	95.33
Routine Urine Examination	1	16.50
Haemoglobin Electrophoresis	1	13.80
Liver Function Test (LFT)	1	155.33
Blood Grouping & Antibody Screen	1	110.00
Fasting Plasma Glucose / Random Plasma Glucose	1	59.40
Glycated Haemoglobin (HbA1c)	1	118.90

Grouping: Breast Cancer Additional Diagnosis Investigations Grouping

Component Investigation	Frequency in Grouping	Unit Cost (GHS)
Cancer Antigen 15-3 (CA 15-3)	1	200.00
Blood Grouping & Antibody Screen	1	110.00
Cytology — Fine Needle Aspiration	1	93.80
Histopathology (large sample)	1	560.00



Component Investigation	Frequency in Grouping	Unit Cost (GHS)
Mammogram	1	550.71

Grouping: Breast Cancer Basic Staging Investigations Grouping

Component Investigation	Frequency in Grouping	Unit Cost (GHS)
CT Scan — 2 regions + contrast*	1	2,247.41

Pre-authorisation required*Grouping: Breast Cancer Additional Staging Investigations Grouping**

Component Investigation	Frequency in Grouping	Unit Cost (GHS)
Bone Scan*	1	1,400.00
CT Scan — 1 region + IV contrast*	1	1,600.00
MRI — 1 region + contrast*	1	2,250.00

Pre-authorisation required*Grouping: Breast Cancer Response Assessment Investigations Grouping (per assessment)**

Component Investigation	Frequency in Grouping	Unit Cost (GHS)
CT Scan — 1 region + IV contrast*	1	1,600.00
Ultrasound — 1 region	1	250.00
Plain X-ray (musculoskeletal, 1 region)	1	110.00
MRI — 1 region + contrast*	1	2,250.00

Pre-authorisation required*Grouping: Post-Surgery Follow-up Investigations Grouping (per follow-up visit)**

Component Investigation	Frequency in Grouping	Unit Cost (GHS)
BUE & Creatinine	1	114.80
Liver Function Tests (LFT)	1	155.33
Full Blood Count (FBC)	1	95.33

Grouping: Chemotherapy Maintenance Basic Investigations Grouping (per cycle)

Component Investigation	Frequency in Grouping	Unit Cost (GHS)
BUE & Creatinine	1	120.00
Liver Function Tests (LFT)	1	180.00
Full Blood Count (FBC)	1	65.00

Grouping: Chemotherapy Maintenance Additional Investigations Grouping (per cycle)

Component Investigation	Frequency in Grouping	Unit Cost (GH¢)
CA 15-3 (tumour marker)	1	200.00
Whole Blood	1	235.00



Component Investigation	Frequency in Grouping	Unit Cost (GH¢)
Concentrated Red Blood Cells	1	235.00
Platelets	1	170.00

Grouping: Hormonal Therapy Basic Investigations Grouping (per visit)

Component Investigation	Frequency in Grouping	Unit Cost (GHS)
BUE & Creatinine	1	114.80
Liver Function Tests (LFT)	1	155.33
Full Blood Count (FBC)	1	95.33

Grouping: Hormonal Therapy Additional Investigations Grouping (per visit)

Component Investigation	Frequency in Grouping	Unit Cost (GHS)
Oestrogen	1	66.12
Progesterone	1	150.00
Follicle Stimulating Hormone (FSH)	1	184.70
Luteinising Hormone (LH)	1	92.10

Grouping: Radiotherapy Investigations Grouping (per visit)

Component Investigation	Frequency in Grouping	Unit Cost (GHS)
BUE & Creatinine	1	114.80
Liver Function Tests (LFT)	1	155.33
Full Blood Count (FBC)	1	95.33

Grouping: Targeted Therapy Basic Investigations Grouping (per visit)

Component Investigation	Frequency in Grouping	Unit Cost (GHS)
BUE & Creatinine	1	114.80
Liver Function Tests (LFT)	1	155.33
Full Blood Count (FBC)	1	95.33

Grouping: Targeted Therapy Additional Investigations Grouping (per visit)

Component Investigation	Frequency in Grouping	Unit Cost (GHS)
Echocardiogram	3	400.00
BRCA Genetic Testing*	1	5,000.00

****Pre-authorisation required***

8. Prostate Cancer

8.1 Clinical Overview and Tariff Narrative

The GMTF covers prostate cancer in adult patients. Five treatment options are covered, divided between Localised Prostate Cancer (LPC, confined to the prostate gland) and Locally Advanced Cancer (LAC, extending beyond the prostate capsule or to regional lymph nodes). All options include a diagnosis phase (2 consultations and the basic diagnosis investigations grouping). The basic staging investigations grouping (CT + MRI) is included for all options. An additional staging investigation grouping (bone scan + additional MRI) is included for LPC and both LAC options where advanced imaging is required to plan treatment.

IMPORTANT: Prostate cancer brachytherapy requires pre-authorisation from the GMTF before the procedure commences. This is a high-cost intervention and claims submitted without documented prior authorisation will not be reimbursed.

8.2 Tariff Schedule

Phase	Item / Service	Frequency	Cost (GHS)
DIAGNOSIS			
	OPD consultation	2	GHS 349.06
	Basic diagnosis investigations (Grouping) — See breakdown below	1	GHS 1,913.23
STAGING			
	OPD consultation	1	GHS 349.06
	Basic staging: CT 2 regions + MRI (Grouping) — See breakdown below	1	GHS 4,497.41
	Additional staging: Bone scan + MRI (Grouping)* — See breakdown below	1	GHS 3,650.00
TREATMENT — SURGERY			
Radical prostatectomy	OPD consultation	1	GHS 349.06
	Open genitourinary surgery	1	GHS 5,426.21
	Anaesthesia — radical prostatectomy	1	GHS 4,702.45
TREATMENT — EBRT (40 fractions)			
	OPD consultation (radiotherapy visits)	40	GHS 349.06



Phase	Item / Service	Frequency	Cost (GHS)
	EBRT IMRT technique — per fraction	40	GHS 544.00
	Radiotherapy consumables — per fraction	40	GHS 112.50
TREATMENT — BRACHYTHERAPY*			
	Ward admission (1 day)	1	GHS 634.15
	Gold seed fiducial marker placement	1	GHS 1,500.00
	Prostate cancer brachytherapy procedure*	1	GHS 101,280.00
TREATMENT — ADT (LAC Options)			
	OPD consultation (4 visits / year)	4	GHS 349.06
	ADT drug costs	—	—
RESPONSE ASSESSMENT (Quarterly — 4 visits/year)			
	OPD consultation (4 visits)	4	GHS 349.06
	Basic response assessment inv. (Grouping, x4 — see breakdown)	4	GHS 217.43
	Hormonal therapy additional investigations (Grouping, x4)* — See breakdown below	4	GHS 492.92

**Pre-authorisation required*

8.3 Investigation Grouping Breakdowns

Grouping: Prostate Cancer Basic Diagnosis Investigations Grouping

Component Investigation	Frequency in Grouping	Unit Cost (GHS)
BUE & Creatinine	1	114.80
Fasting / Random Plasma Glucose	1	59.40
Full Blood Count (FBC)	1	95.33
Blood Grouping & Antibody Screen	1	110.00
Histopathology (small sample)	1	336.60
Routine Urine Examination	1	16.50
Ultrasound-Guided Biopsy	1	648.50
Ultrasound — 2 regions	1	300.00
Prostate Specific Antigen (PSA)	1	122.10
Plain X-ray (musculoskeletal, 1 region)	1	110.00

**Grouping: Prostate Cancer Basic Staging Investigations Grouping**

Component Investigation	Frequency in Grouping	Unit Cost (GHS)
CT Scan — 2 regions + contrast*	1	2,247.41
MRI — 1 region + contrast*	1	2,250.00

Pre-authorisation required*Grouping: Prostate Cancer Additional Staging Investigations Grouping**

Component Investigation	Frequency in Grouping	Unit Cost (GHS)
Bone Scan*	1	1,400.00
MRI — 1 region + contrast*	1	2,250.00

Pre-authorisation required*Grouping: Prostate Cancer Response Assessment Grouping (per quarterly visit)**

Component Investigation	Frequency in Grouping	Unit Cost (GHS)
Prostate Specific Antigen (PSA)	1	122.10
Full Blood Count (FBC)	1	95.33

Grouping: Prostate Cancer Hormonal Therapy Additional Investigations Grouping (per visit)

Component Investigation	Frequency in Grouping	Unit Cost (GHS)
Oestrogen	1	66.12
Progesterone	1	150.00
Follicle Stimulating Hormone (FSH)	1	184.70
Luteinising Hormone (LH)	1	92.10

APPENDIX 2: LIST OF INVESTIGATIONS AND TARIFFS

The following table lists the rates for investigations used in the GMTF tariff calculations. These rates have been developed based on current market rates and are subject to periodic revision. Where an investigation is not listed below but is required by the applicable STG, CHCPs should contact the GMTF for guidance.

No.	Test/Investigation	Unit Cost (GHS)
1.	Alpha-Fetoprotein (AFP)	76.12
2.	Basic Cytogenetic Panel – BCR-ABL Testing	924.00
3.	Basic Cytogenetic Panel using Fluorescence In Situ Hybridisation (FISH) – BCR-ABL1, KMT2A, iAMP21, Hypodiploidy*	1,281.00
4.	Basic Cytogenetic Panel using Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridisation (FISH), and Next Generation Sequencing (NGS) – BCR-ABL1, KMT2A, iAMP21, Hypodiploidy*	1,650.00
5.	Bleeding and Clotting Time	259.50
6.	Blood Culture and Sensitivity	211.42
7.	Blood Grouping	88.00
8.	Blood Grouping and Antibody Screening	110.00
9.	Blood Urea and Creatinine	114.80
10.	Bone Marrow Aspirate	318.70
11.	Bone Marrow Trephine Biopsy	532.59
12.	Bone Scan*	1,400.00
13.	Breast Cancer Gene (BRCA) Test*	5,000.00
14.	Cancer Antigen 15-3 (CA 15-3)	200.00
15.	Computed Tomography (CT) Scan – One Region with Intravenous Contrast*	1,600.00
16.	Computed Tomography (CT) Scan – One Region without Contrast*	1,000.47
17.	Computed Tomography (CT) Scan – Two Regions with One Contrast*	2,247.41
18.	Computed Tomography (CT) Scan – Two Regions with Two Contrasts*	3,079.56
19.	Computed Tomography (CT) Scan – Two Regions without Contrast*	1,851.88
20.	Concentrated Red Blood Cells	235.00
21.	Cytogenetics by Next Generation Sequencing (NGS) – Loss of Heterozygosity (LOH) at 1p and 16q, Gain of 1q, 11p15 LOH/Loss of Imprinting*	924.00
22.	Cytology – Cerebrospinal Fluid	100.00
23.	Cytology – Fine Needle Aspiration	93.80
24.	Doppler Ultrasound Scan – One Region	347.71
25.	Echocardiogram	400.00
26.	Electrocardiogram (ECG)	300.00
27.	Fasting Plasma Glucose / Random Plasma Glucose	59.40
28.	Flow Cytometry for Immunophenotyping	2,600.00



No.	Test/Investigation	Unit Cost (GHS)
29.	Flow Cytometry for Minimal Residual Disease (MRD) – B-cell	5,150.00
30.	Flow Cytometry for Minimal Residual Disease (MRD) – T-cell	6,230.00
31.	Follicle Stimulating Hormone (FSH)	184.70
32.	Full Blood Count (Automated)	95.33
33.	Full Blood Count with Film Comment	145.33
34.	General Anaesthesia Tests	528.73
35.	Glycated Haemoglobin (HbA1c)	118.90
36.	Haemoglobin Electrophoresis	13.80
37.	Hepatitis B Surface Antigen (HBsAg) Screening	41.86
38.	Hepatitis C Screening	41.86
39.	Histopathology (Extra Large Sample)	965.00
40.	Histopathology (Large Sample)	560.00
41.	Histopathology (Medium Sample)	400.00
42.	Histopathology (Small Sample)	336.60
43.	Human Immunodeficiency Virus (HIV) Screening	46.30
44.	Immunostaining*	1,795.54
45.	Ionised Calcium	79.90
46.	Liver Function Test	155.33
47.	Luteinising Hormone (LH)	92.10
48.	Magnetic Resonance Imaging (MRI) – One Region with Contrast*	2,250.00
49.	Magnetic Resonance Imaging (MRI) – One Region without Contrast*	1,450.00
50.	Magnetic Resonance Imaging (MRI) – Two Regions with Contrast*	2,650.00
51.	Malaria Rapid Diagnostic Test (RDT)	6.00
52.	Mammography	550.71
53.	Oestrogen Test	66.12
54.	Paediatric Tests	461.16
55.	Plain Musculoskeletal X-ray – One Region	110.00
56.	Platelets	170.00
57.	Positron Emission Tomography (PET) Scan*	16,000.00
58.	Progesterone Test	150.00
59.	Prostate Specific Antigen (PSA)	122.10
60.	Prothrombin Time / INR	65.44
61.	Routine Stool Examination	15.00
62.	Routine Urine Examination	16.50
63.	Serum Beta Human Chorionic Gonadotropin (β -hCG)	92.10
64.	Serum Inorganic Phosphate	69.50



No.	Test/Investigation	Unit Cost (GHS)
65.	Serum Lactate Dehydrogenase (LDH)	72.00
66.	Serum Magnesium	49.00
67.	Serum Prolactin (PRL)	120.00
68.	Serum Uric Acid	114.80
69.	Ultrasound Scan – One Region	250.00
70.	Ultrasound Scan – Two Regions	300.00
71.	Ultrasound-Guided Biopsy	648.50
72.	Ultrasound-Guided Biopsy	648.50
73.	Ultrasound-Guided Incision and Drainage*	2,832.00
74.	Urine Culture and Sensitivity	128.67
75.	Whole Blood	235.00

**Pre-authorisation required*

IMPORTANT NOTES FOR PROVIDERS

The following points are critical for all Certified Health Care Providers using this Tariff Appendix:

- **Grouping integrity:** Investigation must be claimed based on actual investigations conducted. Patients must not be charged separately for tests included in a grouping.
- **Pre-authorisation:** Items marked with an asterisk (*) in any tariff table require prior authorisation from the GMTF before the service is provided. Submit a Pre-Authorisation Request through the GMTFCare application with clinical justification for approval before proceeding. Claims submitted without documented prior authorisation will not be reimbursed.
- **Drug costs:** Costs of chemotherapy drugs, hormonal therapy agents, targeted therapy agents, ADT drugs, and immunotherapy agents are not included in the tariff schedules. These are covered separately under the GMTF Approved Medicines List.
- **Maintenance phase:** Providers must submit claims for only those maintenance groupings that correspond to the treatment modality actually administered to the patient.
- **Procedures:** Costs of anaesthesia for surgery, and consumables for chemotherapy and radiotherapy are reimbursed separately for procedures.
- **Currency:** All amounts are in Ghana Cedis (GHS) and represent the GMTF reimbursement rate applicable at the time of publication. Tariff rates are subject to periodic review.
- **Queries:** For queries about tariff coding, pre-authorisation, or claims processing, contact the GMTF through your nearest patient navigation officer or via ask@gmtf.gov.gh or +233 (0)34 229 5105.

